EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Real-World Results of the Single Intravitreal Injection of Faricimab in Treatment-Naïve Subfoveal Myopic Choroidal Neovascularization

Hao-Chun Chang, Ling-Uei Wang iD, Tzu-Lun Huang, Pei-Yao Chang, Wei-Ting Ho, Yung-Ray Hsu, Fang-Ting Chen iD, Yun-Ju Chen, Cheng-Hung Lin iD, Jia-Kang Wang iD

Medicina · 27.04.2026 · 62 (5) · 832

DOI: 10.3390/medicina62050832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, online erschienen am 27.04.2026. Verfasst von Hao-Chun Chang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Choroidal Neovascularization, Myopia, Degenerative. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Myopic choroidal neovascularization (mCNV) is a vision-threatening complication of pathologic myopia. While anti-VEGF monotherapy is the current standard of care, recurrence and suboptimal responses remain challenges. Faricimab is a novel bispecific antibody that targets both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) to improve vascular stability. This study aims to evaluate the short-term efficacy and safety of a single intravitreal faricimab injection in eyes with active mCNV. Materials and Methods: This retrospective, single-center study included 27 eyes from 24 patients with active mCNV, including both treatment-naïve and previously treated cases. All eyes received a single intravitreal injection of faricimab (6.0 mg/0.05 mL). Best-corrected visual acuity (BCVA) in logMAR and central retinal thickness (CRT) via spectral-domain optical coherence tomography were assessed at baseline and one month post injection. Statistical significance was determined using paired and independent t-tests (p < 0.05).

Results

The study population (mean age 55.5 ± 13.9 years; mean axial length 29.3 ± 1.6 mm) showed significant improvements at one month. Mean BCVA improved from 0.77 ± 0.71 logMAR to 0.51 ± 0.52 logMAR (p < 0.005). Mean CRT decreased from 290.2 ± 66.0 μm to 242.5 ± 45.7 μm (p < 0.005). No ocular adverse events, such as intraocular inflammation, retinal detachment, or endophthalmitis, were observed.

Conclusions

A single intravitreal injection of faricimab provides significant short-term functional and anatomical improvement in this small retrospective series. Dual inhibition of VEGF-A and Ang-2 appears to be a safe and effective approach for stabilizing retinal vasculature in patients with high myopia. Larger, long-term prospective studies are needed to determine optimal treatment intervals for mCNV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificChoroidal NeovascularizationMyopia, DegenerativeIntravitreal InjectionsAngiogenesis InhibitorsVisual AcuityTomography, Optical CoherenceVascular Endothelial Growth Factor ARetinaRetrospective StudiesHumansMaleFemaleAdultMiddle AgedAgedTreatment Outcome

Stichwörter der Autor:innen

faricimabintravitreal injectionmyopic choroidal neovascularization

Substanzen

faricimabAngiogenesis InhibitorsAntibodies, BispecificVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
  • Department of Medicine, National Yang Ming Chiao Tung University, Taipei City 112, Taiwan.
  • Department of Electrical Engineering, Yuan Ze University, Taoyuan City 320, Taiwan.
  • Department of Medicine, National Taiwan University, Taipei City 100, Taiwan.
  • Department of Electrical Engineering, National Taiwan Normal University, Taipei City 106, Taiwan.

ORCID-Profile: Ling-Uei Wang, Fang-Ting Chen, Cheng-Hung Lin, Jia-Kang Wang

Förderung

  • National Science and Technology Council

Zitieren

APA

Chang, H. C., Wang, L. U., Huang, T. L., Chang, P. Y., Ho, W. T., Hsu, Y. R., Chen, F. T., Chen, Y. J., Lin, C. H., & Wang, J. K. (2026). The Real-World Results of the Single Intravitreal Injection of Faricimab in Treatment-Naïve Subfoveal Myopic Choroidal Neovascularization. Medicina, 62(5), 832. https://doi.org/10.3390/medicina62050832

Vancouver

Chang HC, Wang LU, Huang TL, Chang PY, Ho WT, Hsu YR, et al. The Real-World Results of the Single Intravitreal Injection of Faricimab in Treatment-Naïve Subfoveal Myopic Choroidal Neovascularization. Medicina. 2026;62(5):832. doi:10.3390/medicina62050832

BibTeX
@article{Chang2026,
  author = {Chang, Hao-Chun and Wang, Ling-Uei and Huang, Tzu-Lun and Chang, Pei-Yao and Ho, Wei-Ting and Hsu, Yung-Ray and Chen, Fang-Ting and Chen, Yun-Ju and Lin, Cheng-Hung and Wang, Jia-Kang},
  title = {The Real-World Results of the Single Intravitreal Injection of Faricimab in Treatment-Naïve Subfoveal Myopic Choroidal Neovascularization},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {5},
  pages = {832},
  doi = {10.3390/medicina62050832}
}
Kostenlos starten →